Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VVUS: VIVUS INC. (NASDAQ) -- Ignore unavailable to you. Want to Upgrade?

To: VLAD who wrote (13116)	8/12/1998 9:00:00 AM
From: BigKNY3	Respond to of 23519

Vlad <<Your assumption that big pharma has no interest in "small products" such as MUSE again demonstrates your bias.Apparently a big pharma by the name of Astra thinks otherwise. Apparently a big pharma by the name of janssen thinks otherwise.>> Vlad: I am not sure where you think there is a "bias" against VVUS. The divesting of small products from Big Pharma is an established trend. Message 5343078 The Astra deal was concluded in May, 1996 and the Jansssen agreement in January 1997. Much has happened since that time. Both agreements were signed prior to the following; the launch of MUSE in the US, the assumption that oral medications would be available on the international markets in 2000, the potential impact of oral medication on MUSE specification, and the continuing impact of managed care on physicians' time. BigKNY3